New -Lactamase Inhibitors Nacubactam and Zidebactam Improve the in Vitro Activity of -Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

Research output: Contribution to journalArticle

Abstract

The new diazabicyclooctane-based -lactamase inhibitors avibactam and relebactam improve the in vitro activity of -lactam antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based -lactamase inhibitors in clinical development, nacubactam and zidebactam, with -lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner -lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other -lactams, similar to prior results with avibactam and relebactam.

Original languageEnglish (US)
Article numbere00733-19
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number9
DOIs
StatePublished - 2019

Keywords

  • -lactamase inhibitors
  • -lactams
  • Cefepime
  • Diazabicyclooctane
  • Drug susceptibility assay
  • Meropenem
  • Mycobacterium abscessus
  • Nacubactam
  • Zidebactam

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'New -Lactamase Inhibitors Nacubactam and Zidebactam Improve the in Vitro Activity of -Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates'. Together they form a unique fingerprint.

  • Cite this